Latest News

Vancouver, BC – October 18, 2022 – Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”), an actively managed, psychedelics industry-focused investment issuer, today announced that one

Toronto, ON – September 22, 2022 – Origin Therapeutics Holdings Inc. (CSE: ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce that

Origin is pleased to announce the election of Michael Galego as a new director of the Company. Vancouver, B.C. – September 13, 2022 – Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”),

Clairvoyant aims to develop and validate psychedelic therapy using psilocybin to treat addiction in Canada, the E.U., and the U.K.  Vancouver, B.C. – July 7, 2022 – Origin Therapeutics Holdings

Vancouver, B.C. – June 14, 2022 – Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, is applauding the recent announcement from

The Company will commence trading on June 6, 2022 under the symbol “ORIG” on the Canadian Securities Exchange Vancouver, B.C. – June 2, 2022 – Origin Therapeutics Holdings Inc. (the

Vancouver, B.C. & Toronto, ON – May 17, 2022 – Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce

Vancouver, B.C. & Toronto, ON – March 29, 2022 – Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”), an actively managed, psychedelic-focused investment issuer, is pleased to announce that

Origin Therapeutics’ portfolio company, Microdose Psychedelic Insights, will host the Microdose Psychedelic Capital event virtually on March 24 Vancouver, British Columbia – March 23, 2022 – Origin Therapeutics Holdings Inc.

Vancouver, British Columbia – January 27, 2022 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in

Microdose Psychedelic Insights’ Wonderland: Miami conference was the largest in-person conference in the psychedelic medicine business Vancouver, B.C. – January 20, 2022 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the

Vancouver, B.C. – December 1, 2021 – Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, where

Vancouver, British Columbia, November 15, 2021 – Origin Therapeutics Holdings Inc. (the “Company” or “Origin Therapeutics”), an actively managed investment issuer focused on making equity investments in private, psychedelics-related companies

Origin Therapeutics Holdings Inc. is announcing that its portfolio company TripSitter Clinic Corp. has expanded its service to patients in Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia.

Wonderland: Miami is hosted by Microdose Psychedelic Insights, an Origin Therapeutics portfolio company. Vancouver, British Columbia – October 20, 2021 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company”

Origin Therapeutics Holdings Inc. announces that it has filed its preliminary long form prospectus dated August 30, 2021 with the securities regulatory authorities in the provinces of British Columbia, Ontario, and Alberta.

Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed), an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.